ResMed (RMD) Divestiture of MatrixCare presentation summary

Transaction overview

• Signed agreement to divest MatrixCare business to Frazier Healthcare Partners, expected to close in Q1 FY27.

• All-cash transaction valued at $490 million, subject to closing adjustments.

• Proceeds will be used for shareholder returns, including an accelerated share repurchase program, and general corporate purposes.

• MatrixCare generated approximately $220 million in revenue and $55 million in non-GAAP operating profit in FY26.

• Transition service agreements will be in place to manage operational continuity and stranded costs post-closing.

Strategic rationale and portfolio impact

• Portfolio optimization sharpens focus on core growth areas: sleep, breathing, and connected home-based care.

• Residential Care Software segment will consist of Brightree and MEDIFOX DAN after the transaction.

• RCS segment expected to accelerate to high single-digit revenue growth with operating leverage in FY27.

• Capital will be reallocated toward higher-growth, higher-return opportunities.

• Supports expansion of the digital health ecosystem and progress toward 2030 strategy.

Financial and outlook considerations

• Noctrix expected to contribute ~$30M in revenue and reduce non-GAAP EPS by ~$0.20 in FY27.

• FY26 outlook for non-GAAP gross margin, SG&A, R&D, and tax rate reiterated.

• FY27 outlook to be provided during Q4 FY26 earnings call.

• Non-GAAP financial measures are used alongside GAAP, with reconciliations available in earnings releases.

• Forward-looking statements are subject to risks and actual results may differ materially.